[Ip-health] NY Times_Abbott Labs to Split Into 2 Companies

Peter Maybarduk pmaybarduk at citizen.org
Thu Oct 18 13:19:41 PDT 2012


http://dealbook.nytimes.com/2011/10/19/abbott-to-split-into-two/

"Abbott Laboratories said on Wednesday that it would separate next year into two publicly traded companies, one focused on diagnostics and medical devices like heart stents and the other on what it called "research-based pharmaceuticals," like Humira, its blockbuster rheumatoid arthritis drug."

http://seekingalpha.com/article/544061-long-opportunity-the-abbott-labs-split-strategy

"A good summary of the split was presented at the JPMorgan Healthcare Conference in January. A "Research-Based Pharmaceutical" company will be spun off, and renamed AbbVie. This will include a line of proprietary drugs, anchored by the product Humira, sales of which are growing at a rate in excess of 20% per year, and also a portfolio of new drugs which are now in the R&D pipeline."

"Here is some detail of the potential product line of AbbVie, which shows that most of the growth in this business between 2010 and 2011 was outside the US:

[see link above] 




More information about the Ip-health mailing list